Skip to main content
. 2024 Jul 29;14:17459. doi: 10.1038/s41598-024-68338-2

Figure 3.

Figure 3

PFS by subgroups including (a) platinum sensitivity (b) BRCA mutation status, (c) previous PARP inhibitor (PARPi) therapy exposure, (d) FIGO stage at diagnosis, and (e) ECOG performance status at the start of therapy. ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, MV multivariate, NE not evaluable, PARP poly(ADP-ribose) polymerase, PFS progression-free survival, UV univariate.